INT80018

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 1999
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 2.84
Pain Relevance 0.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (ERBB4) mitochondrion (ERBB4) cytoplasm (ERBB4)
cell proliferation (ERBB4) cytosol (ERBB4) signal transduction (ERBB4)
ERBB4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Chronic pancreatitis 1 94.88 High High
Inflammation 37 50.00 Quite Low
Central nervous system 42 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
Pain 5 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Bioavailability 4 5.00 Very Low Very Low Very Low
addiction 4 5.00 Very Low Very Low Very Low
tolerance 4 5.00 Very Low Very Low Very Low
palliative 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 160 99.68 Very High Very High Very High
Pancreatic Cancer 4 99.08 Very High Very High Very High
Pancreatitis 1 94.88 High High
Inflammatory Breast Neoplasms 134 94.52 High High
Metastasis 40 87.04 High High
Shock 1 87.04 High High
Apoptosis 7 68.92 Quite High
Advanced Or Metastatic Breast Cancer 69 66.16 Quite High
Breast Cancer 80 58.16 Quite High
Stomach Cancer 47 56.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In pancreatic cancer, 61 of 75 samples exhibited weak to moderate immunoreactivity for erbB-4 in the tumor cells.
erbB-4 Binding (immunoreactivity) of associated with cancer and pancreatic cancer
1) Confidence 0.35 Published 1999 Journal Int. J. Cancer Section Abstract Doc Link 9988227 Disease Relevance 0.83 Pain Relevance 0.09
Molecular interactions between HER2 and other members of its family (HER1 or EGFR, HER3 and HER4) have led to the development of new targeted therapies such as the anti-EGFR monoclonal antibody cetuximab, the anti-EGFR oral small molecule tyrosine kinase inhibitors erlotinib and gefitinib, and the dual EGFR-HER2 tyrosine kinase inhibitor lapatinib [96].
HER4 Binding (interactions) of
2) Confidence 0.17 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.57 Pain Relevance 0
No association was seen for ErbB4, PTEN or c-MYC.
ErbB4 Neg (No) Binding (association) of
3) Confidence 0.17 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.27 Pain Relevance 0
EREG (epiregulin) belongs to the EGF growth factor family that binds both ERBB1 and ERBB4.
ERBB4 Binding (binds) of
4) Confidence 0.16 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064141 Disease Relevance 0.90 Pain Relevance 0
ErbB2, whilst having no exogenous ligand, is the preferred partner for heterodimerization with ErbB1, ErbB3 and ErbB4 as it amplifies the mitogenic signal with potent growth and survival effects.
ErbB4 Binding (heterodimerization) of
5) Confidence 0.13 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.27 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox